CRBU - Company ID 0001619856
Caribou Biosciences, Inc. trades as CRBU. In its fiscal 2025 annual report the company posted revenue of $11.16M, up 11.7% from the prior year and net income of -$148.13M. This page tracks Caribou Biosciences, Inc. through 316 SEC filings, with financial statements and metrics updated as new reports are filed.
Research snapshot
Updated
With latest filings
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
Next research step
Over the last 6 fiscal years Caribou Biosciences, Inc.'s revenue grew from $5.79M to $11.16M, a compound annual growth rate of 11.6%. Net profit margin compressed from -404.8% to -1327.4% over the same period - every figure below comes from the company's audited annual filings.
Dig into the full income statement, balance sheet, and cash flow statement with annual and quarterly views.
| Filing | Type | Filed |
|---|---|---|
| Quarterly report | 10-Q | 2026-05-07 |
| Major company event | 8-K | 2026-05-07 |
| DEFR14A | - | 2026-05-01 |
| Annual report to shareholders | ARS | 2026-04-24 |
| Proxy materials | DEFA14A | 2026-04-24 |
| Proxy statement | DEF 14A | 2026-04-24 |
| PRE 14A | - | 2026-04-10 |
| Major company event | 8-K | 2026-03-31 |
The largest companies sharing Caribou Biosciences, Inc.'s SEC industry classification (biological products, (no diagnostic substances)).
Caribou Biosciences, Inc. reported revenue of $11.16M for fiscal year 2025, an increase of 11.7% year over year.
In its latest fiscal year Caribou Biosciences, Inc. reported a net loss of $148.13M.